For research use only. Not for therapeutic Use.
T-2307, an arylamidine, has antifungal activities in vitro and in vivo. T-2307 exhibits broad-spectrum activity against clinically significant pathogens, including Candida species (MIC range, 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range, 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range, 0.0156 to 4 μg/mL) [1].
T-2307 exhibits potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent Candida albicans strains as well as against azole-susceptible strains[1].
T-2307 shows efficacy in a murine model of candida glabrata infection despite in vitro trailing growth phenomena[2].
In mouse models of disseminated candidiasis, cryptococcosis, and aspergillosis, the ED50 of T-2307 were 0.00755, 0.117, and 0.391 mg/kg, respectively[1].
| Catalog Number | I045584 |
| CAS Number | 873546-31-7 |
| Synonyms | 4-[3-[1-[3-(4-carbamimidoylphenoxy)propyl]piperidin-4-yl]propoxy]benzenecarboximidamide |
| Molecular Formula | C25H35N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H35N5O2/c26-24(27)20-4-8-22(9-5-20)31-17-1-3-19-12-15-30(16-13-19)14-2-18-32-23-10-6-21(7-11-23)25(28)29/h4-11,19H,1-3,12-18H2,(H3,26,27)(H3,28,29) |
| InChIKey | KUNDLEJVAIBADY-UHFFFAOYSA-N |
| SMILES | C1CN(CCC1CCCOC2=CC=C(C=C2)C(=N)N)CCCOC3=CC=C(C=C3)C(=N)N |
| Reference | [1]. Junichi Mitsuyama, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008 Apr;52(4):1318-24. [2]. Eio Yamada, et al. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother. 2010 Sep;54(9):3630-4. |
